On Nov 09, major Wall Street analysts update their ratings for $Ligand Pharmaceuticals (LGND.US)$, with price targets ranging from $135 to $150.
Barclays analyst Balaji Prasad maintains with a buy rating, and adjusts the target price from $125 to $150.
Oppenheimer analyst Leland Gershell maintains with a buy rating, and adjusts the target price from $135 to $147.
Oppenheimer analyst Trevor Allred initiates coverage with a buy rating, and sets the target price at $147.
Craig-Hallum analyst Matt Hewitt maintains with a buy rating, and sets the target price at $140.
Benchmark Co. analyst Robert Wasserman maintains with a buy rating, and adjusts the target price from $110 to $135.
Furthermore, according to the comprehensive report, the opinions of $Ligand Pharmaceuticals (LGND.US)$'s main analysts recently are as follows:
Following a quarter that outperformed expectations and led to raised forecasts, it's noted that the company's positive outlook is supported by robust performance across its three principal revenue channels.
Ligand's third-quarter financial outcomes surpassed expectations on the revenue front, and the company has elevated its full-year revenue forecast for fiscal year 2024 to a range of $160 million to $165 million. This projection is deemed cautious by analysts in light of the robust performance of royalty assets, coupled with the acceleration of early product launches and the possibility of expanded usage for various indications.
Here are the latest investment ratings and price targets for $Ligand Pharmaceuticals (LGND.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
